AnalystsSara NikSara Nik's Stock Forecasts
AnalystsSara Nik
Sectors:
Industries:
Analyst Ranking
Top 29%
#1506 out of 5256 analysts
Average Return
+33.47%
Win Rate
45%5 out of 11
Risk vs Reward
Poor
Good
Sara Nik's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Cidara Therapeutics IncCDTX | +257.06% | $62.00 | $221.38 | 2025-08-07 - 2026-01-06 | Buy |
Cidara Therapeutics IncCDTX | +144.63% | $90.50 | $221.38 | 2025-09-25 - 2026-01-06 | Buy |
Cidara Therapeutics IncCDTX | +114.47% | $103.22 | $221.38 | 2025-10-20 - 2026-01-06 | Buy |
Cidara Therapeutics IncCDTX | +99.87% | $110.76 | $221.38 | 2025-10-08 - 2026-01-06 | Buy |
Moleculin Biotech IncMBRX | +13.78% | $2.25 | $2.56 | 2026-03-23 - 2026-04-20 | Buy |
Sara Nik Analyst Color
Get additional color on Sara Nik's coverage of popular stocks
Sara Nik's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Pasithea Therapeutics CorpKTTA | 2 | Buy | $3.00 | +318.41% | Reiterates | 20 hours ago |
Moleculin Biotech IncMBRX | 4 | Buy | $22.00 | +759.38% | Reiterates | a month ago |
Curis IncCRIS | 1 | Buy | $17.00 | +2,655.27% | Reiterates | a month ago |
Cidara Therapeutics IncCDTX | 4 | Buy | $150.00 | -32.24% | Reiterates | 6 months ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.